产品说明书

Rosiglitazone maleate

Print
Chemical Structure| 155141-29-0 同义名 : BRL 49653C;Rosiglitazone (maleate);Avandaryl;Avandia
CAS号 : 155141-29-0
货号 : A332359
分子式 : C22H23N3O7S
纯度 : 98%
分子量 : 473.499
MDL号 : MFCD03427306
存储条件:

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度 :

DMSO: 105 mg/mL(221.75 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方:
生物活性
描述 Rosiglitazone maleate, a potent and selective activator of PPARγ, exhibits EC50 values of 30 nM and 100 nM for PPARγ1 and PPARγ2, respectively, and a Kd of approximately 40 nM for PPARγ. Rosiglitazone (BRL49653) at concentrations of 0.1, 1, 10 μM, promotes the differentiation of C3H10T1/2 stem cells into adipocytes[1]. Rosiglitazone activates PPARγ with an EC50 of 60 nM[2]. Rosiglitazone (1 μM) activates PPARγ, which binds to the NF-α1 promoter, enhancing gene transcription in neurons. Additionally, Rosiglitazone (1 μM) protects Neuro2A cells and hippocampal neurons against oxidative stress and upregulates BCL-2 expression in an NF-α1-dependent manner[3]. Rosiglitazone effectively blocks TRPM3 channels with IC50 values of 9.5 μM and 4.6 μM against nifedipine- and PregS-evoked activities, respectively, through mechanisms not involving PPARγ. It also inhibits TRPM2 channels at a higher concentration, with an IC50 of approximately 22.5 μM. Additionally, Rosiglitazone acts as a potent activator of TRPC5 channels, with an EC50 of about 30 μM[4].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
HepG2 cells Function assay Peroxisome proliferator activated receptor gamma agonistic activity in HepG2 cells, EC50=0.73 μM 10714503
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00306696 Diabetes Mellitus Phase 4 Completed - -
NCT00367055 Type 2 Diabetes Mellitus Phase 4 Completed - -
NCT00367055 - Completed - -
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.11mL

0.42mL

0.21mL

10.56mL

2.11mL

1.06mL

21.12mL

4.22mL

2.11mL

参考文献

[1]Lehmann JM, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995 Jun 2;270(22):12953-6.

[2]Willson TM, et al. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem. 1996 Feb 2;39(3):665-8.

[3]Thouennon E, et al. Rosiglitazone-activated PPARγ induces neurotrophic factor-α1 transcription contributing to neuroprotection. J Neurochem. 2015 Aug;134(3):463-70.

[4]Majeed Y, et al. Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels. Mol Pharmacol. 2011 Jun;79(6):1023-30.

[5]Ateyya H, et al. Beneficial effects of rosiglitazone and losartan combination in diabetic rats. Can J Physiol Pharmacol. 2018 Mar;96(3):215-220.